Deciphera downgraded to Market Perform from Outperform at Leerink

Leerink downgraded Deciphera to Market Perform from Outperform with a price target of $25.60, down from $34, after Japanese pharma company Ono Pharmaceutical announced it would acquire Deciphera in an all-cash transaction for $25.60 per share. The firm notes that the boards of directors of both companies unanimously approved the transaction and it sees little risk of deal closure.